Dopamine receptor

Source: Wikipedia, the free encyclopedia.

Dopamine

Dopamine receptors are a class of

endogenous ligand
for dopamine receptors.

Dopamine receptors are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of

of dopamine receptors.

Subtypes

The existence of multiple types of receptors for dopamine was first proposed in 1976.[3][4] There are at least five subtypes of dopamine receptors, D1, D2, D3, D4, and D5. The D1 and D5 receptors are members of the D1-like family of dopamine receptors, whereas the D2, D3 and D4 receptors are members of the D2-like family. There is also some evidence that suggests the existence of possible D6 and D7 dopamine receptors, but such receptors have not been conclusively identified.[5]

At a global level, D1 receptors have widespread expression throughout the brain. Furthermore, D1-2 receptor subtypes are found at 10–100 times the levels of the D3-5 subtypes.[6]

D1-like family

The

G. D1 is also coupled to Golf
.

G subsequently activates adenylyl cyclase, increasing the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP).[7]

D2-like family

The

cAMP by inhibiting the enzyme adenylyl cyclase.[8]

Receptor heteromers

Dopamine receptors have been shown to heteromerize with a number of other

G protein-coupled receptors.[15] Especially the D2 receptor is considered a major hub within the GPCR heteromer network.[16] Protomers
consist of

Isoreceptors[17]

  • D1–D2
  • D1–D3
  • D2–D3
  • D2–D4
  • D2–D5

Non-isoreceptors

Signaling mechanism

DARPP-32, an inhibitor of protein phosphatase 1. Sustained D1 receptor activity is kept in check by Cyclin-dependent kinase 5. Dopamine receptor activation of Ca2+/calmodulin-dependent protein kinase II can be cAMP dependent or independent.[18]

The cAMP mediated pathway results in amplification of PKA phosphorylation activity, which is normally kept in equilibrium by PP1. The DARPP-32 mediated PP1 inhibition amplifies PKA phosphorylation of AMPA, NMDA, and inward rectifying potassium channels, increasing AMPA and NMDA currents while decreasing potassium conductance.[7]

cAMP independent

D1 receptor agonism and D2 receptor blockade also increases mRNA translation by phosphorylating

BDNF independent of cAMP, possibly through direct interactions. There is evidence that D1 receptor agonism regulates phospholipase C independent of cAMP, however implications and mechanisms remain poorly understood. D2 receptor signaling may mediate protein kinase B, arrestin beta 2, and GSK-3 activity, and inhibition of these proteins results in stunting of the hyperlocomotion in amphetamine treated rats. Dopamine receptors can also transactivate Receptor tyrosine kinases.[18]

Beta Arrestin recruitment is mediated by G-protein kinases that phosphorylate and inactivate dopamine receptors after stimulation. While beta arrestin plays a role in receptor desensitization, it may also be critical in mediating downstream effects of dopamine receptors. Beta arrestin has been shown to form complexes with MAP kinase, leading to activation of

PP2A protein complex that inhibits Akt through PP2A phosphorylation, therefore disinhibiting GSK-3.[19]

Role in the central nervous system

Dopamine receptors control neural signaling that modulates many important behaviors, such as

emesis and motor function.[21]

Non-CNS dopamine receptors

Cardio-pulmonary system

In humans, the

myocardium, and endocardium of the heart.[23] In rats, D1-like receptors are present on the smooth muscle of the blood vessels in most major organs.[24]

D4 receptors have been identified in the

myocardial contractility and cardiac output, without changing heart rate, by signaling through dopamine receptors.[5]

Renal system

Dopamine receptors are present along the

sympathetic nerve terminals.[24] Dopamine signaling affects diuresis and natriuresis.[5]

The Pancreas

The role of the pancreas[26] is to secrete digestive enzymes via exocrine glands and hormones via endocrine glands. Pancreatic endocrine glands, composed of dense clusters of cells called the Islets of Langerhans, secrete insulin, glucagon, and other hormones essential for metabolism and glycemic control. Insulin secreting beta cells have been intensely researched due to their role in diabetes.[27]

Recent studies have found that beta cells, as well as other endocrine and exocrine pancreatic cells, express D2 receptors[28] and that beta cells co-secrete dopamine along with insulin.[29] Dopamine has been purported to be a negative regulator of insulin,[30][31] meaning that bound D2 receptors inhibit insulin secretion. The connection between dopamine and beta cells was discovered, in part, due to the metabolic side-effects of certain antipsychotic medications.[32][33] Traditional/typical antipsychotic medications function by altering the dopamine pathway in the brain, such as blocking D2 receptors.[34] Common side effects of these medications include rapid weight gain and glycemic dysregulation, among others.[35] The effects of these medications are not limited to the brain, so off-target effects in other organs such as the pancreas have been proposed as a possible mechanism.[36]

In disease

Dysfunction of dopaminergic neurotransmission in the CNS has been implicated in a variety of neuropsychiatric disorders, including

attention-deficit hyperactivity disorder (ADHD),[41] and drug and alcohol dependence.[38][42]

Attention-deficit hyperactivity disorder

Dopamine receptors have been recognized as important components in the mechanism of ADHD for many years. Drugs used to treat ADHD, including methylphenidate and amphetamine, have significant effects on neuronal dopamine signaling. Studies of gene association have implicated several genes within dopamine signaling pathways; in particular, the D4.7 variant of D4 has been consistently shown to be more frequent in ADHD patients.[43] ADHD patients with the 4.7 allele also tend to have better cognitive performance and long-term outcomes compared to ADHD patients without the 4.7 allele, suggesting that the allele is associated with a more benign form of ADHD.[43]

The D4.7 allele has suppressed gene expression compared to other variants.[44]

Addictive drugs

Dopamine is the primary neurotransmitter involved in the

substituted amphetamines, inhibit the dopamine transporter (DAT), the protein responsible for removing dopamine from the neural synapse. When DAT activity is blocked, the synapse floods with dopamine and increases dopaminergic signaling. When this occurs, particularly in the nucleus accumbens,[49] increased D1[42] and decreased D2[49] receptor signaling mediates the "incentive salience" factor and can significantly increase positive associations with the drug in the brain.[48]

Pathological gambling

Pathological gambling is classified as a mental health disorder that has been linked to obsessive-compulsive spectrum disorder and behavioral addiction. Dopamine has been associated with reward and reinforcement in relation to behaviors and drug addiction.[50] The role between dopamine and pathological gambling may be a link between cerebrospinal fluid measures of dopamine and dopamine metabolites in pathological gambling.[51] Molecular genetic study shows that pathological gambling is associated with the TaqA1 allele of the Dopamine Receptor D2 (DRD2) dopamine receptor. Furthermore, TaqA1 allele is associated with other reward and reinforcement disorders, such as substance abuse and other psychiatric disorders. Reviews of these studies suggest that pathological gambling and dopamine are linked; however, the studies that succeed in controlling for race or ethnicity, and obtain DSM-IV diagnoses do not show a relationship between TaqA1 allelic frequencies and the diagnostic of pathological gambling.[50]

Schizophrenia

While there is evidence that the dopamine system is involved in schizophrenia, the theory that hyperactive dopaminergic signal transduction induces the disease is controversial. Psychostimulants, such as amphetamine and cocaine, indirectly increase dopamine signaling; large doses and prolonged use can induce symptoms that resemble schizophrenia. Additionally, many antipsychotic drugs target dopamine receptors, especially D2 receptors.

Genetic hypertension

Dopamine receptor

animal models and humans with defective dopamine receptor activity, particularly D1.[24]

Parkinson's disease

Parkinson's disease is associated with the loss of cells responsible for dopamine synthesis and other neurodegenerative events.[50] Parkinson's disease patients are treated with medications which help to replenish dopamine availability, allowing relatively normal brain function and neurotransmission.[53] Research shows that Parkinson's disease is linked to the class of dopamine agonists instead of specific agents. Reviews touch upon the need to control and regulate dopamine doses for Parkinson's patients with a history of addiction, and those with variable tolerance or sensitivity to dopamine.[54]

Dopamine regulation

Dopamine receptors are typically stable, however sharp (and sometimes prolonged) increases or decreases in dopamine levels can downregulate (reduce the numbers of) or upregulate (increase the numbers of) dopamine receptors.[55]

Haloperidol, and some other antipsychotics, have been shown to increase the binding capacity of the D2 receptor when used over long periods of time (i.e. increasing the number of such receptors).[56] Haloperidol increased the number of binding sites by 98% above baseline in the worst cases, and yielded significant dyskinesia side effects.

Addictive stimuli have variable effects on dopamine receptors, depending on the particular stimulus.[57] According to one study,[58] cocaine, opioids like heroin, amphetamine, alcohol, and nicotine cause decreases in D2 receptor quantity. A similar association has been linked to food addiction, with a low availability of dopamine receptors present in people with greater food intake.[59][60] A recent news article[61] summarized a U.S. DOE Brookhaven National Laboratory study showing that increasing dopamine receptors with genetic therapy temporarily decreased cocaine consumption by up to 75%. The treatment was effective for 6 days. Cocaine upregulates D3 receptors in the nucleus accumbens, further reinforcing drug seeking behavior.[62] and Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain,[63] Caffeine, or other more selective adenosine A2A receptor antagonists, causes significantly less motor stimulation in dopamine D2 receptor.[64]

Certain stimulants will enhance cognition in the general population (e.g., direct or indirect

DRD1 agonists as a class), but only when used at low (therapeutic) concentrations.[65][66][67] Relatively high doses of dopaminergic stimulants will result in cognitive deficits.[66][67]

Summary of addiction-related plasticity
Form of neuroplasticity
or behavioral plasticity
Type of reinforcer Sources
Opiates Psychostimulants High fat or sugar food Sexual intercourse Physical exercise
(aerobic)
Environmental
enrichment
MSNs
Tooltip medium spiny neurons
[57]
Behavioral plasticity
Escalation of intake Yes Yes Yes [57]
Psychostimulant
cross-sensitization
Yes Not applicable Yes Yes Attenuated Attenuated [57]
Psychostimulant
self-administration
[57]
Psychostimulant
conditioned place preference
[57]
Reinstatement of drug-seeking behavior
[57]
Neurochemical plasticity
CREBTooltip cAMP response element-binding protein phosphorylation

in the nucleus accumbens
[57]
Sensitized dopamine response
in the nucleus accumbens
No Yes No Yes [57]
Altered striatal dopamine signaling
DRD3
DRD3
DRD3
DRD2
DRD2
[57]
Altered striatal opioid signaling No change or
μ-opioid receptors
μ-opioid receptors
κ-opioid receptors
μ-opioid receptors μ-opioid receptors No change No change [57]
Changes in striatal opioid peptides dynorphin
No change: enkephalin
dynorphin enkephalin dynorphin dynorphin [57]
Mesocorticolimbic synaptic plasticity
Number of dendrites in the nucleus accumbens [57]
Dendritic spine density in
the nucleus accumbens
[57]

See also

References

  1. S2CID 21432517
    .
  2. .
  3. .
  4. .
  5. ^ .
  6. .
  7. ^ .
  8. .
  9. ^ a b "Introduction to Neuroscience".
  10. S2CID 46096849
    .
  11. ^ NCBI Database
  12. PMID 12192625
    .
  13. .
  14. .
  15. .
  16. .
  17. .
  18. ^ .
  19. .
  20. .
  21. .
  22. .
  23. .
  24. ^ .
  25. .
  26. , retrieved 12 April 2024
  27. .
  28. .
  29. .
  30. .
  31. .
  32. .
  33. .
  34. .
  35. .
  36. .
  37. .
  38. ^ .
  39. PMID 17017512. {{cite book}}: |journal= ignored (help
    )
  40. .
  41. .
  42. ^ .
  43. ^ .
  44. .
  45. .
  46. .
  47. .
  48. ^ a b "Drugs and the Brain". National Institute on Drug Abuse. 22 March 2022. Retrieved 21 August 2022.
  49. ^
    S2CID 25983940
    .
  50. ^ .
  51. .
  52. .
  53. .
  54. .
  55. .
  56. .
  57. ^
    PMID 21459101. Cross-sensitization is also bidirectional, as a history of amphetamine administration facilitates sexual behavior and enhances the associated increase in NAc DA ... As described for food reward, sexual experience can also lead to activation of plasticity-related signaling cascades. The transcription factor delta FosB is increased in the NAc, PFC, dorsal striatum, and VTA following repeated sexual behavior (Wallace et al., 2008; Pitchers et al., 2010b). This natural increase in delta FosB or viral overexpression of delta FosB within the NAc modulates sexual performance, and NAc blockade of delta FosB attenuates this behavior (Hedges et al, 2009; Pitchers et al., 2010b). Further, viral overexpression of delta FosB enhances the conditioned place preference for an environment paired with sexual experience (Hedges et al., 2009). ... In some people, there is a transition from "normal" to compulsive engagement in natural rewards (such as food or sex), a condition that some have termed behavioral or non-drug addictions (Holden, 2001; Grant et al., 2006a). ... In humans, the role of dopamine signaling in incentive-sensitization processes has recently been highlighted by the observation of a dopamine dysregulation syndrome in some patients taking dopaminergic drugs. This syndrome is characterized by a medication-induced increase in (or compulsive) engagement in non-drug rewards such as gambling, shopping, or sex (Evans et al, 2006; Aiken, 2007; Lader, 2008)."Table 1
    "
  58. .
  59. ^ Park P (9 August 2007). "Food Addiction: From Drugs to Donuts, Brain Activity May be the Key".
  60. PMID 20348917
    .
  61. ^ "Gene Therapy For Addiction: Flooding Brain With 'Pleasure Chemical' Receptors Works On Cocaine, As On Alcohol". 18 April 2008.
  62. PMID 8815892
    .
  63. .
  64. .
  65. . The present meta-analysis was conducted to estimate the magnitude of the effects of methylphenidate and amphetamine on cognitive functions central to academic and occupational functioning, including inhibitory control, working memory, short-term episodic memory, and delayed episodic memory. In addition, we examined the evidence for publication bias. Forty-eight studies (total of 1,409 participants) were included in the analyses. We found evidence for small but significant stimulant enhancement effects on inhibitory control and short-term episodic memory. Small effects on working memory reached significance, based on one of our two analytical approaches. Effects on delayed episodic memory were medium in size. However, because the effects on long-term and working memory were qualified by evidence for publication bias, we conclude that the effect of amphetamine and methylphenidate on the examined facets of healthy cognition is probably modest overall. In some situations, a small advantage may be valuable, although it is also possible that healthy users resort to stimulants to enhance their energy and motivation more than their cognition. ... Earlier research has failed to distinguish whether stimulants' effects are small or whether they are nonexistent (Ilieva et al., 2013; Smith & Farah, 2011). The present findings supported generally small effects of amphetamine and methylphenidate on executive function and memory. Specifically, in a set of experiments limited to high-quality designs, we found significant enhancement of several cognitive abilities. ...

    The results of this meta-analysis cannot address the important issues of individual differences in stimulant effects or the role of motivational enhancement in helping perform academic or occupational tasks. However, they do confirm the reality of cognitive enhancing effects for normal healthy adults in general, while also indicating that these effects are modest in size.
  66. ^ . Mild dopaminergic stimulation of the prefrontal cortex enhances working memory. ...
    Therapeutic (relatively low) doses of psychostimulants, such as methylphenidate and amphetamine, improve performance on working memory tasks both in normal subjects and those with ADHD. Positron emission tomography (PET) demonstrates that methylphenidate decreases regional cerebral blood flow in the doroslateral prefrontal cortex and posterior parietal cortex while improving performance of a spatial working memory task. This suggests that cortical networks that normally process spatial working memory become more efficient in response to the drug. ... [It] is now believed that dopamine and norepinephrine, but not serotonin, produce the beneficial effects of stimulants on working memory. At abused (relatively high) doses, stimulants can interfere with working memory and cognitive control ... stimulants act not only on working memory function, but also on general levels of arousal and, within the nucleus accumbens, improve the saliency of tasks. Thus, stimulants improve performance on effortful but tedious tasks ... through indirect stimulation of dopamine and norepinephrine receptors.
  67. ^ .

External links